PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35469489-5	2022	These agents include polatuzumab vedotin, tafasitamab, loncastuximab tesirine, selinexor, and anti-CD19 chimeric antigen receptor T-cell therapies such as axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.	axicabtagene	155-167	CD19 molecule	Homo sapiens	99-103	
34041526-0	2021	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.	axicabtagene	84-96	CD19 molecule	Homo sapiens	0-4	
33385585-1	2021	Axicabtagene ciloleucel or axi-cel (CD19-CAR T-cells) has been recently approved for refractory/ relapsed diffuse large B cell lymphoma and primary mediastinal B-cell lymphoma.	axicabtagene	0-12	CD19 molecule	Homo sapiens	36-40	
32670869-7	2020	Here we provide a thorough review on the use of the anti-CD19 CAR T-cell products axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel in patients with indolent or aggressive B-cell lymphoma or with chronic lymphocytic leukemia, and present novel CAR T cell-based approaches currently under investigation in these disease settings.	axicabtagene	82-94	CD19 molecule	Homo sapiens	57-61	
35012754-8	2022	Here we provide a thorough review on the use of the FDA approved anti-CD19 CAR T-cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel in patients with indolent or aggressive B-cell lymphoma, and touch on mechanisms of failure of CAR T-cell therapy and potential approaches which are currently under investigation to address this.	axicabtagene	95-107	CD19 molecule	Homo sapiens	70-74	
33448873-1	2021	Axicabtagene ciloleucel and brexucabtagene autoleucel are anti-CD19 T-cell therapies that utilize the same second-generation chimeric antigen receptor with a CD28 costimulatory subunit.	axicabtagene	0-12	CD19 molecule	Homo sapiens	63-67